1-9 of 9
Joseph Flynn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Ta-Ming Liu, Jennifer A. Woyach, Yiming Zhong, Arletta Lozanski, Gerard Lozanski, Shuai Dong, Ethan Strattan, Amy Lehman, Xiaoli Zhang, Jeffrey A. Jones, Joseph Flynn, Leslie A. Andritsos, Kami Maddocks, Samantha M. Jaglowski, Kristie A. Blum, John C. Byrd, Jason A. Dubovsky, Amy J. Johnson
Journal: Blood
Blood (2015) 126 (1): 61–68.
https://doi.org/10.1182/blood-2015-02-626846
Published: 2015
Includes: Supplemental data
Journal Articles

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma

Clinical Trials & Observations
Kami Maddocks, Beth Christian, Samantha Jaglowski, Joseph Flynn, Jeffery A. Jones, Pierluigi Porcu, Lai Wei, Cynthia Jenkins, Gerard Lozanski, John C. Byrd, Kristie A. Blum
Journal: Blood
Blood (2015) 125 (2): 242–248.
https://doi.org/10.1182/blood-2014-08-597914
Published: 2015
Journal Articles

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

Clinical Trials & Observations
Jennifer A. Woyach, Kelly Smucker, Lisa L. Smith, Arletta Lozanski, Yiming Zhong, Amy S. Ruppert, David Lucas, Katie Williams, Weiqiang Zhao, Laura Rassenti, Emanuela Ghia, Thomas J. Kipps, Rose Mantel, Jeffrey Jones, Joseph Flynn, Kami Maddocks, Susan O’Brien, Richard R. Furman, Danelle F. James, Fong Clow, Gerard Lozanski, Amy J. Johnson, John C. Byrd
Journal: Blood
Blood (2014) 123 (12): 1810–1817.
https://doi.org/10.1182/blood-2013-09-527853
Published: 2014
Includes: Supplemental data
Journal Articles

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

Sarah E. M. Herman, Amber L. Gordon, Erin Hertlein, Asha Ramanunni, Xiaoli Zhang, Samantha Jaglowski, Joseph Flynn, Jeffrey Jones, Kristie A. Blum, Joseph J. Buggy, Ahmed Hamdy, Amy J. Johnson, John C. Byrd
Journal: Blood
Blood (2011) 117 (23): 6287–6296.
https://doi.org/10.1182/blood-2011-01-328484
Published: 2011
Journal Articles

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody

Farrukh T. Awan, Rosa Lapalombella, Rossana Trotta, Jonathan P. Butchar, Bo Yu, Don M. Benson, Jr, Julie M. Roda, Carolyn Cheney, Xiaokui Mo, Amy Lehman, Jeffrey Jones, Joseph Flynn, David Jarjoura, John R. Desjarlais, Susheela Tridandapani, Michael A. Caligiuri, Natarajan Muthusamy, John C. Byrd
Journal: Blood
Blood (2010) 115 (6): 1204–1213.
https://doi.org/10.1182/blood-2009-06-229039
Published: 2010
Journal Articles

A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation

Kristie A. Blum, MD, Zhongfa Liu, David M. Lucas, Robert Baiocchi, Thomas S. Lin, Don Benson, Steven M. Devine, Jeffrey Jones, Leslie Andritsos, Joseph Flynn, Ping Cheng, Zhiliang Xie, Guido Marcucci, Kenneth K. Chan, Michael R. Grever, John C. Byrd
Journal: Blood
Blood (2008) 112 (11): 3169.
https://doi.org/10.1182/blood.V112.11.3169.3169
Published: 2008
Journal Articles

Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL).

Leslie Andritsos, Mehdi Hamadani, Nyla A. Heerema, PhD, Don Benson, Craig C. Hofmeister, MD, William Blum, MD, Joseph Flynn, Jeffrey Alan Jones, MD, Patrick Elder, Thomas S. Lin, Gerard Lozanski, John C. Byrd, Steven Devine
Journal: Blood
Blood (2008) 112 (11): 2170.
https://doi.org/10.1182/blood.V112.11.2170.2170
Published: 2008
Journal Articles

A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin’s Lymphoma

Kristie A. Blum, MD, Robert A. Baiocchi, Lapo Alinari, Thomas S. Lin, Pierluigi Porcu, Jeffrey Jones, Joseph Flynn, William Hicks, Margaret S. Lucas, Lai Wei, Jeffrey S. Johnston, John C. Byrd
Journal: Blood
Blood (2008) 112 (11): 3053.
https://doi.org/10.1182/blood.V112.11.3053.3053
Published: 2008
Journal Articles

Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Don Benson, Leslie Andritsos, Mehdi Hamadani, Thomas Lin, Joseph Flynn, Jeffrey Jones, William Blum, MD, Patrick Elder, Gerard Lozanski, John Byrd, Steven Devine
Journal: Blood
Blood (2008) 112 (11): 3300.
https://doi.org/10.1182/blood.V112.11.3300.3300
Published: 2008